The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A phase II study of chemoselection with docetaxel, cisplatin, and 5–fluorouracil as a strategy for organ preservation in patients with resectable esophageal cancer (CROC trial).
 
Chikatoshi Katada
Research Funding - Yakult Honsha (Inst)
 
Hiroki Hara
No Relationships to Disclose
 
Hirofumi Fujii
No Relationships to Disclose
 
Takako Eguchi Nakajima
Honoraria - Amgen; Bayer; Bristol-Myers Squibb Japan; Chugai Pharma; Daiichi Sankyo; Dainippon Sumitomo; Lilly Japan; MERCK SERONO; MSD; Nippon Boehringer Ingelheim; Nippon Kayaku; Nipro Corporation; Novartis; Ono Pharmaceutical; Pfizer; Sanofi; Taiho Pharmaceutical; Takeda; Yakult Honsha
Research Funding - A2 Healthcare; Astellas Pharma; Bayer; Bristol Myers Squibb Foundation; Chugai Pharma; Daiichi Sankyo; Dainippon Sumitomo Pharma; Eisai; ICON Clinical Research; Japan Clinical Research Operations; Lilly Japan; Mediscience Planning; Merck Serono; MSD K.K; Nippon Kayaku; Ono Pharmaceutical; PAREXEL; Sanofi; Solasia Pharma; Taiho Pharmaceutical; Takeda
 
Takayuki Ando
No Relationships to Disclose
 
Motoo Nomura
Research Funding - Canon Medical System
 
Takashi Kojima
Honoraria - BMS; MSD; Oncolys BioPharma; Ono Pharmaceutical
Consulting or Advisory Role - Astellas Pharma; BMS; Merck; MSD; Ono Pharmaceutical
Research Funding - Astellas Amgen BioPharama (Inst); Chugai Pharma (Inst); MSD (Inst); Ono Pharmaceutical (Inst); Shionogi (Inst); Taiho Pharmaceutical (Inst)
 
Keishi Yamashita
No Relationships to Disclose
 
Tetsuji Yokoyama
No Relationships to Disclose
 
Yasutoshi Sakamoto
No Relationships to Disclose
 
Hiroki Sasaki
No Relationships to Disclose
 
Yusuke Inoue
No Relationships to Disclose
 
Shogo Kawakami
No Relationships to Disclose
 
Hideki Ishikawa
No Relationships to Disclose
 
Ayumu Hosokawa
Honoraria - Chugai Pharma; Daiichi Sankyo; Eisai; Lilly; Merck; Novartis; Ono Pharmaceutical; Sanofi; Taiho Pharmaceutical; Takeda; Teijin Pharma
Research Funding - Chugai Pharma (Inst); Eisai (Inst); Hisamitsu Pharmaceutical (Inst); Ono Pharmaceutical (Inst); Taiho Pharmaceutical (Inst); Yakult Honsha (Inst)
 
Yasuo Hamamoto
No Relationships to Disclose
 
Manabu Muto
No Relationships to Disclose
 
Makoto Tahara
Honoraria - Bristol-Myers Squibb; Eisai; Merck Serono; MSD; Ono Pharmaceutical
Consulting or Advisory Role - Bayer; Bristol-Myers Squibb; Lilly; MSD; Ono Pharmaceutical; Pfizer; Rakuten Medical
Research Funding - AstraZeneca (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); GlaxoSmithKline (Inst); Lilly (Inst); Loxo (Inst); Merck Sharp & Dohme (Inst); Novartis (Inst); Ono Pharmaceutical (Inst); Pfizer (Inst); Rakuten Medical (Inst)
 
Wasaburo Koizumi
Research Funding - Yakult Honsha (Inst)